$35.57
+0.84 (+2.42%)
Open$34.73
Previous Close$34.73
Day High$36.07
Day Low$33.92
52W High$45.97
52W Low$28.95
Volume—
Avg Volume692.7K
Market Cap1.71B
P/E Ratio103.54
EPS$0.26
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+22.6% upside
Current
$35.57
$35.57
Target
$43.60
$43.60
$27.22
$43.60 avg
$49.94
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 254.71M | 214.24M | 156.14M |
| Net Income | 15.23M | 11.53M | 35.53M |
| Profit Margin | 6.0% | 5.7% | 22.8% |
| EBITDA | 20.79M | 16.61M | 44.60M |
| Free Cash Flow | — | — | 32.60M |
| Rev Growth | +18.9% | +18.9% | +24.7% |
| Debt/Equity | 0.01 | 0.01 | 0.62 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |